Disease & disorder

parathyroid gland carcinoma

MONDO:0012004

A very rare, slow-growing, clinically serious endocrine tumor that generally develops in mid-adulthood. PRTC presents as a palpable painless mass in the neck and causes severe hypercalcemia and related symptoms, non-specific gastrointestinal manifestations, as well as renal and bone complications related to primary hyperparathyroidism (nephrolithiasis, impaired renal function, osteoporosis, bone pain, and pathologic fractures, etc.). Some PRTCs are however non-functioning tumors.

Clinical trials3

Recruiting1

Drug concepts studied1

Synonyms22

Disease research snapshot

CureCurrent currently links 3 distinct registered clinical trials to parathyroid gland carcinoma through its MONDO disease mappings. 1 of those studies have the registry status “recruiting” (33%). These are registry statuses, not availability guarantees, study results or evidence of effectiveness.

The leading sponsor shown in this linked dataset is Instituto do Cancer do Estado de São Paulo, associated with 1 distinct linked trials. This is a count of records, not a ranking of the sponsor's scientific quality.

The highest-count mapped research city in the current result is Lebanon, United States. Only site locations available in the published registry projection are counted; some trial sites may be missing or outdated.

The most frequently mapped drug concept in the current linked trials is nivolumab (1 distinct trials). This describes what has been studied, not a recommended treatment.

Numbers are derived from CureCurrent's current ClinicalTrials.gov projection and conservative MONDO/RxNorm mappings. See sources, counting rules and limitations and verify eligibility or clinical findings with the original study record.

Research intelligence

Directly mapped studies only · unique clinical trials

Current registry observations. Phase counts may overlap. Study start dates are not registry registration dates. Investigational interventions are not approved-treatment recommendations.